Latest Strategy News

Talga Group has applied for a SEK 1.1 billion grant to fund a commercial-scale battery anode plant in Sweden, complementing existing EU funding and securing strong customer interest.

Corazon Mining has successfully raised $1.8 million through a placement to fast-track exploration at its Two Pools and Feather Cap gold projects in Western Australia. The funding sets the stage for maiden drilling programs in early 2026, aiming to confirm high-grade historical results.

Sunrise Energy Metals has raised A$18.865 million through a premium-priced share placement to fast-track pre-construction at its Syerston Scandium Project, reinforcing its path toward becoming a primary scandium supplier.

OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.

Mammoth Minerals has raised A$7.5 million through a placement to accelerate exploration at its high-grade Excelsior and Bella Gold Projects in Nevada, aiming to unlock significant gold potential.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Aureka has reported compelling high-grade gold assay results from its ongoing drilling at the Irvine Project in Victoria, revealing a newly identified Resolution Footwall Vein and extending known mineralisation beyond the current resource boundary.

QuickFee Limited has completed a $28.5 million capital return following the sale of its US Pay Now and Connect businesses, while updating its dividend policy to target regular shareholder cash distributions starting in FY26.

Transurban Group has announced a 34-cent unfranked dividend per stapled security for the six months ending December 2025, alongside a Dividend Reinvestment Plan with no discount.

Control Bionics Limited is set to acquire the remaining stake in Neuro Elite Athletics, integrating the NeuroBounce athletic performance program with its EMG technology to accelerate growth in key markets.

Island Pharmaceuticals has secured over $1 million through option exercises by directors and major shareholders, bolstering its cash reserves to advance the clinical and regulatory development of its broad-spectrum antiviral, Galidesivir.